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Summary
Latexin, the only known mammalian carboxypepti-
dase inhibitor, has no detectable sequence similarity
with plant and parasite inhibitors, but it is related to
a human putative tumor suppressor protein, TIG1.
Latexin is expressed in the developing brain, and we
find that it plays a role in inflammation, as it is ex-
pressed at high levels and is inducible in macro-
phages in concert with other protease inhibitors and
potential protease targets. The crystal structure of
mouse latexin, solved at 1.83 Å resolution, shows no
structural relationship with other carboxypeptidase
inhibitors. Furthermore, despite a lack of detectable
sequence duplication, the structure incorporates two
topologically analogous domains related by pseudo
two-fold symmetry. Surprisingly, these domains share
a cystatin fold architecture found in proteins that inhibit
cysteine proteases, suggesting an evolutionary and
possibly functional relationship. The structure of the
tumor suppressor protein TIG1 was modeled, reveal-
ing its putative membrane binding surface.
Introduction
Latexin, or tissue carboxypeptidase inhibitor (TCI), is
the only known mammalian carboxypeptidase inhibitor
(CPI), and recombinant rat latexin has been shown to
inhibit pancreatic carboxypeptidase A1 (CPA1), CPA2
(Ki w3 nM), and CPA3 (mast cell carboxypeptidase, Ki
16 nM) (Normant et al., 1995). Comprising over 220 resi-
dues, the protein is significantly larger than CPIs from
plants and parasites (40–70 residues). Furthermore, la-
texin lacks the conserved 7-residue C terminus of these
shorter CPIs that interacts with CPA in a substrate-like
manner (Reverter et al., 2000). The loss of the C termi-
nus suggests that latexin and the plant/parasite CPIs
have distinctly different mechanisms of CPA inhibition.
Latexin was first identified as a marker of neurons in*Correspondence: j.martin@imb.uq.edu.authe lateral neocortex (hence latexin) of the developing
mammalian brain (Arimatsu, 1994). It has been used to
elucidate the mechanism of cortical regional specifica-
tion, and it was suggested to play a role in the modula-
tion of sensory perception (Bai et al., 2004). It is thought
that latexin functions in inflammation and innate im-
mune pathways because it is expressed by rat mast
cells, it inhibits mast cell CPA3, and it localizes to a
novel population of mast cell granules, distinct from the
classical exocytic granule classes (Uratani et al., 2000).
Furthermore, latexin is induced in acute pancreatitis
and lung inflammatory disease (Ji et al., 2003). Here,
we present new evidence for a role for latexin in inflam-
mation by showing that its expression is induced in
stimulated mouse macrophages in concert with poten-
tial protease targets and other protease inhibitors.
Although unrelated to known CPIs, latexin does
share sequence similarity with TIG1 (Figure 1, w30%
identity over 220 residues), a protein found in mouse,
rat, and human. TIG1 is expressed in skin fibroblasts
and epithelia, and it is encoded by a retinoic acid (RA)
receptor-responsive gene. It has been implicated in
both the therapeutic effects of RA in psoriasis (Nagpal
et al., 1996) and, more recently, in tumor suppression
(Jing et al., 2002). TIG1 is larger than latexin, and the
additional residues are thought to encode a membrane
anchor at the N terminus (Nagpal et al., 1996).
Other proteins with sequence identity (w30%) to la-
texin are found in chicken (ovocalyxin [Hincke et al.,
2003]) and Xenopus (Figure 1), but no related proteins
were found in nonvertebrates. Chicken ovocalyxin is a
protein involved in egg shell production. This similarity,
the vertebrate-restricted gene family, and the reported
expression of latexin in osteoblasts (Balint et al., 2003)
suggest roles for latexin in bone regulation and calcifi-
cation.
To gain insight into the function of latexin, we investi-
gated its expression profile in macrophages, deter-
mined its crystal structure, and used the structure to
model that of TIG1. The latexin structure reveals unex-
pected pseudosymmetry and a previously unknown re-
lationship with the cysteine protease inhibitor cystatin.
Results
Latexin Is Macrophage Enriched and Inducible
In light of a possible role for latexin in inflammation, we
examined expression in macrophages, the major cell
type recruited to acute and chronic inflammatory sites.
We have previously reported extensive analyses of
gene expression profiles in mouse macrophages from
several mouse strains (Wells et al., 2003a). These analy-
ses indicate that the gene encoding latexin forms part
of a set that is highly enriched in macrophages com-
pared to other cell types and tissues, and is highly ex-
pressed in macrophage-rich tissues such as spleen and
liver (Wells et al., 2003b). The latexin gene also fell
within a cluster of genes induced in macrophages by
the major lineage-specific growth factor, colony stimu-
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310Figure 1. Sequence Alignments
(A) Multiple sequence alignment of mouse, rat, and human latexin (m_latexin, NP_058033.2; r_latexin, NP_113843.1; h_latexin, AAF82807.1);
human, rat, and mouse TIG1 (h_TIG1, AAH29640.1; r_TIG1, XP_227232.2; m_TIG1, XP_130987.2); Xenopus laevis latexin-like protein (Xp_
unknown, AAH59975.1); and chicken ovocalyxin (CAC44378.2). The number of N- or C-terminal residues not shown in the alignment are
indicated in parentheses. Residue numbers and secondary structure for mouse latexin are shown. Residues conserved throughout are shaded
in dark gray, and where the residue is conserved in all but one, it is shaded in light gray.
(B) Structure-based sequence alignment of the N- and C-terminal latexin domains (Lxn1 and Lxn2, respectively), chicken cystatin (cCYS, PDB
accession code 1CEW [Bode et al., 1988]), human Stefin B (hSTFB, 1STF [Stubbs et al., 1990]), and monellin (MONB and MONA, respectively,
for the two peptides, 1MOL [Somoza et al., 1993]). Residues that can be structurally aligned with the N-terminal domain of latexin are
highlighted in light gray. Residues that are identical—after structural alignment—with the N-terminal domain of latexin are highlighted in dark
gray, and residues from human Stefin B that interact with the cysteine protease papain (1STF [Stubbs et al., 1990]) are shaded in black.lating factor 1 (CSF-1), in combination with the patho- a
egen product, lipopolysaccharide (LPS).
To confirm the latexin expression profile identified by c
using cDNA microarrays, we performed real-time PCR
analysis in LPS-stimulated bone marrow-derived macro- S
Bphages in the presence or absence of CSF-1. Latexin
mRNA was, indeed, expressed at high levels in macro- t
tphages, and it was further induced by a combination of
LPS and CSF-1 (Figure 2). Other genes induced by LPS A
iin murine macrophages included CPA3 (mast cell CP),
a known interaction partner of latexin, carboxypepti- l
pdase D (this has been noted previously, Hadkar and
Skidgel, 2001), and the cysteine protease inhibitors m
cystatin C and cystatin F (Figure 2). Indeed, w8% of
genes upregulated under this stimulation encode prote- fses or protease inhibitors. By comparison, TIG1 gene
xpression is also high in macrophages but does not
hange upon stimulation.
tructure of Latexin
ased upon its expression profile in macrophages, la-
exin and its target CPA represent potential targets for
herapeutic intervention in chronic inflammatory disease.
s no latexin homologs with known structures could be
dentified, we determined its structure by X-ray crystal-
ography by using MAD methods and SeMet-labeled
rotein. The structure has one molecule in the asym-
etric unit and was refined at 1.83 Å resolution (Table 1).
Although there is no evidence of internal symmetry
rom the polypeptide sequence, the crystal structure re-
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311Figure 2. Expression in Macrophages
(A) Quantitative real-time PCR profiles of latexin mRNA showing
dynamic expression after LPS stimulation in macrophages over
time, in concert with other protease inhibitors and potential target
proteases. The expression peak for latexin is at 7 hr, when the mac-
rophage response to LPS also reaches a maximum.
(B) Quantitative real-time PCR profiles of latexin mRNA showing
the effect of the growth factor CSF-1. The plotted data have been
normalized as described in the Experimental Procedures.tatin-like protein as a consequence of a gene duplica-mains can be superimposed on the other, simulta-
Table 1. Data Collection and Refinement Statistics
Data Collection
MAD (SeMet) Native
Wavelength (Å) 0.9794 0.9796 0.9077 1.0781
Resolution range (Å) 50–1.96 50–1.96 50–1.96 50–1.83 (1.9–1.83)a
Observed reflections 413,797 392,101 399,913 426,598
Unique reflections 22,703 22,622 22,591 29,633
Rmergeb 0.073 0.071 0.060 0.039 (0.422)a
Completeness (%) 99.9 99.9 99.1 99.7 (100)a
<I>/<σ(I)> 18.5 15.3 12.8 19.9 (4.5)a
Refinement
Resolution of data used in refinement 50.0–1.83 (1.94–1.83)a
Number of reflections total/test set 28,971/2,897
Rfacc and Rfreed (%) 21.1 (25.9)a and 23.7 (26.8)a
Number of protein atoms/waters 1,871/184
Rmsd from ideal geometry: bonds (Å)/angles (°) 0.011/1.5
Ramachandran: most favored/disallowed regions (%) 91.3/0.0
a Parentheses refer to the highest resolution shell.
b Rmerge = S|I − <I>|/S<I>; I is the intensity of each reflection.
c Rfac = Sh|Fo − Fc|/Sh|Fo|; Fo and Fc are observed and calculated structure-factor amplitudes for each reflection, h.
d Rfree for 10% of data selected randomly and excluded from refinement.veals two structurally related domains (domains 1 and
2) linked by a connecting helix (α2) (Figure 3). Each do-
main comprises a five-stranded antiparallel β sheet
wrapped around an α helix. The sequence identity be-
tween the two domains is w11% after structural align-
ment (Figure 1B), yet the Cα atoms of 84 residues of
domains 1 and 2 overlay with an rmsd of 1.9 Å. Extra-
ordinarily, the pseudosymmetry is such that both do-neously giving an rmsd of 2.1 Å for the Cα atoms of 142
aligned residues (Figure 3).
The major structural differences between the two do-
mains are variations in β strand lengths and different
loop conformations and sizes. This is particularly strik-
ing for the loop connecting the first β strand and the α
helix of each domain (β1-α1 and β6-α3, respectively).
In domain 2, this loop comprises 11 residues (residues
121–131) that protrude from the core, while the equiva-
lent loop in domain 1 is formed from five residues (resi-
dues 4–8) (Figure 1B).
Latexin Comprises Two Cystatin-like Folds
No other protein was found to have the same overall
topology as latexin (DALI [Holm and Sander, 1993]);
however, the individual domains share the topology of
the cystatin/monellin family of proteins (Figure 4) (Mur-
zin et al., 1995). Cystatins are cysteine protease inhibi-
tors, and monellin is a sweet-tasting protein from the
West African berry Dioscoreophyllum cumminsii (So-
moza et al., 1993). The cystatin/monellin fold is charac-
terized by a five-stranded antiparallel β sheet and a
central α helix. The structure of chicken cystatin (Bode
et al., 1988) is the most similar to latexin (rmsd of 1.6 Å
and 14 [17%] identical residues for the comparison of
84 Cα atoms with the latexin N-terminal domain).
Although there is no overall sequence relationship
between latexin and cystatins (Figure 1B), the structural
relationship suggests an evolutionary and possibly a
functional relationship. When submitted as individual
domains, the meta-server 3D-JURY (Ginalski et al.,
2003) predicted the sequence of domain 1, but not do-
main 2, to have a cystatin-like structure. Furthermore,
in the genes encoding both human and mouse latexin,
the position between domains 1 and 2 corresponds to
an intron-exon boundary, with each domain encoded
by three exons (data not shown). These data suggest
that latexin may have evolved from an ancestral cys-
Structure
312Figure 3. Crystal Structure
(A) Stereo diagram of the electron density
(2Fo-Fc contoured at 2σ) around the cis-pro-
line region (Ile122-cisPro123-Asp-124).
(B) Schematic of the latexin structure show-
ing β strands as arrrows and α helices as
spirals. The N-terminal subdomain (residues
1–97) is red, the C-terminal subdomain (resi-
dues 118–222) is orange, and the linking α
helix is green.
(C) Superposition of the two subdomains,
residues 1–97 (red) on residues 118–222
(green) and residues 118–222 (red) on resi-
dues 1–97 (green). Some loops were re-
moved for clarity.
(D) Surface renderings of latexin showing
(left) a putative binding surface predicted
from PROMATE (Neuvirth et al., 2004); the
best-predicted binding surface is shown in
blue, the less probable binding surface is
shown in white, and the least probable bind-
ing surface is shown in red. The surface on
the right shows the conservation of residues
across the three mammalian latexins, ovo-
calyxin, and Xenopus latexin-like protein
(which together make one branch in the phy-
logenetic tree, with the TIG1 proteins form-
ing another branch). The color scheme is
green for highly conserved residues, white
for less conserved proteins, and yellow for
least conserved proteins.
The figure was generated by using GRASP
(Nicholls et al., 1993), MOLSCRIPT (Kraulis,
1991), and Raster3D (Merritt and Murphy,
1994) or by using BOBSCRIPT (Esnouf, 1999)
and Povray (www.povray.org).tion event. The overall gene structure for cystatins is a
tsimilar to that for the individual domains of latexin in
that there are three exons and two introns. However, r
athe length and sequence of the introns and exons are
not conserved between cystatins and latexin domains, b
Ysuggesting that if the latexin N-terminal domain evolved
from an ancestral cystatin, the divergence would have d
occurred early in evolution. The presence of two cys- 1
tatin-like domains also suggests the possibility that t
cleavage may be required for activity. However, there is t
no evidence of cleavage of recombinant mouse latexin; v
it forms a stable complex with bovine CPA (data not p
shown). i
bCarboxypeptidase Binding
vCrystal structures of the potato and leech CPIs in com-
cplex with CPA2 revealed that the C-terminal tail of the
(inhibitors interacts with the active site of CPA in a sub-
lstrate-like manner (Rees and Lipscomb, 1982; Reverter
et al., 2000). The C-terminal residues (-Pro-Tyr-Val-X) qre conserved in these inhibitors, but not in latexin;
herefore, a common mechanism of inhibition can be
uled out (Normant et al., 1995). Previous sequence
nalysis studies identified a limited degree of similarity
etween an 11-residue sequence of latexin (200-LWHPQ
GTKVK-210) and the prosegment of carboxypepti-
ase B (CPB) (37-FWKPDSATQVK-47) (Normant et al.,
995). It was therefore suggested that this region of la-
exin may inhibit CPs by mimicking the prosegment of
he enzymes. However, the two sequence motifs form
ery different secondary structures in their respective
roteins, indicating that this mechanism of inhibition
s unlikely.
We used structural approaches to identify potential
inding sites on latexin. The program ProMate (Neu-
irth et al., 2004) identified a surface patch that in-
ludes residues 174-FI-175, 204-PQ-205, and T208
Figure 3D). This region from the C-terminal domain of
atexin includes the residues that are similar in se-
uence to the proCPB region described above, and it
Cellular and Structural Studies on Latexin
313Figure 4. Diversity and Similarity in CP Inhibi-
tors, Cystatin, and Monellin
(A–F) Structures of CP inhibitors from (A) po-
tato (4CPA [Rees and Lipscomb, 1982]) and
(B) leech (1DTV [Reverter et al., 2000]) are
very different from the structure of mamma-
lian CP inhibitor, (C) latexin. However, latexin
(N-terminal domain, [D]) is structurally re-
lated to proteins in the (E) cystatin (cysteine
protease inhibitor, chicken cystatin) (1CEW
[Bode et al., 1988]) and (F) monellin (sweet-
tasting protein) (1MOL [Somoza et al., 1993])
fold family.also includes a loop equivalent to one of the papain-
interacting regions of the cystatin human Stefin B
(170-RNDDFI-175 of latexin, corresponding to VAGT of
human Stefin B, highlighted in Figure 1B). Some con-
served residues also map to this area of the surface
(Figure 3D), though this analysis is hampered by the
low number of latexin sequences available.
Heparin and Sulfate Binding
Latexin also interacts directly with a heparin compo-
nent in the mast cell population of granules (Uratani et
al., 2000). We identified the potential binding surface by
using GRID (Goodford, 1985) with a sulfate anion probe.
At high-energy contour levels (−9.0 kcal/mol), a sulfate
binding site was observed near Arg171. Analysis of the
electrostatic properties of the protein surface (GRASP
[Nicholls et al., 1993]) supports the identification of this
basic patch as a sulfate binding site. Moreover, the
close proximity of another basic patch, formed by resi-
dues Lys208, Lys210, and His211 on strand 9, could
coordinate other sulphates on a heparin sulfate oligo-
mer. This hypothesis is supported by docking a mast
cell granule heparin sulfate pentasaccharide onto the
mouse latexin surface. Of 50 solutions, 43 had a sulfate
group in the vicinity of the proposed sulfate binding
pocket identified by GRID, and 26 had another sulfate
positioned close to the basic patch.
Conservation of a cis-Proline Motif
The structure of latexin incorporates a cis-peptide
bond between residues Ile122 and Pro123. These resi-
dues are located in a protruding loop between the first
β strand (β6) and α helix (α3) of domain 2. The density
in this region is well defined (Figure 3), and the se-
quence in this region (IPDXXG) is conserved throughout
the latexin/TIG1 family of proteins (Figure 1). Indeed,
with four of six residues conserved in all eight proteins,
this is the most highly conserved motif in the entire se-
quence. This high degree of conservation in a family ofproteins that are related overall by only 30% identity
suggests that the cis form of the peptide bond will also
be present in TIG1 and the Xenopus and ovocalyxin
proteins. Furthermore, the position of the cis-proline
motif on a protruding loop is suggestive of a protein
interaction surface.
Structure of TIG1
Alignment of latexin and TIG1 sequences illustrates
that differences exist between the two proteins as well
as within the TIG1 family. The most notable of these is
the presence of a variable length N-terminal extension
in TIG1 relative to latexin (Figure 1) that is predicted to
form a transmembrane helix.
Models of human latexin and human TIG1 were de-
rived by homology modeling based on the crystal struc-
ture of mouse latexin. The electrostatic surfaces of hu-
man latexin and human TIG1 (Figure 5) show that the
two proteins have strikingly different charge distribu-
tions on one face, with TIG1 having a predominantly
basic surface. This surface may interact with mem-
branes, given that human TIG1 is predicted to be mem-
brane bound. The opposite face of TIG1 has features
common to latexin. A basic patch is present in a similar
location to that created by Lys18 and Lys159 in mouse
latexin and Lys159 in human latexin. The surface
around this patch is more hydrophobic in human TIG1
compared to human latexin (due to substitutions of
Lys159 to Tyr, Ile62 to Tyr, Glu33 to Val, and Gln18 to
Leu), and the negative patch at the helix 2 end of the
cleft is reduced in size. Furthermore, the residues defin-
ing the heparin binding site identified in the mouse la-
texin structure, and also present in the human and rat
latexin isoforms, are not conserved in TIG1.
Discussion
Latexin is the only known mammalian carboxypepti-
dase inhibitor. We have found that latexin is expressed
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p(A–D) Electrostatic surfaces are shown for (A and B) human latexin
and (C and D) TIG1 based on models derived from the crystal struc- s
ture of mouse latexin. The broadly basic surface of (C) TIG1—absent c
in (A) latexin—suggests an interaction surface for phospholipid p
membranes, consistent with a predicted membrane anchor at the oN terminus of TIG1. (B and D) A basic patch on the opposite face
hof both proteins is indicated. This is also present, and more promi-
vnent, in mouse latexin (not shown). The figure was produced by
using GRASP (Nicholls et al., 1993). o
l
sconstitutively at high basal levels in mouse macro-
c
phages and can be further upregulated by stimulation
i
of the cells with a growth factor or proinflammatory
n
stimulus. Upregulation occurs in parallel with several
other types of protease inhibitors and target proteases. p
The known targets of latexin are the three isoforms of e
CPA, though it is possible that latexin may interact with o
and regulate the activity of other proteases. e
Nevertheless, the available data strongly suggest a t
role for CPA and latexin in inflammation, and other CPs, m
including CPM, have been shown to correlate with t
macrophage cytotoxic activity (Rehli et al., 2000). CPA i
has been reported to be involved in the production or a
regulation of several proinflammatory mediators. In vi- t
tro, CPA from mast cells degrades endothelin-1, raising s
the possibility that it limits endothelin-mediated vaso- i
constriction and proliferation (Metsarinne et al., 2002).
Pancreatic CPA has also been shown to convert the s
potent leukotriene C4 to the less potent leukotriene F4 t
by hydrolysis of an amide bond, again suggesting a S
negative role in inflammation (Reddanna et al., 2003). s
However, purified bovine CPA can induce NFκB-depen- b
dent TNFα production from macrophages, suggesting a a
proinflammatory role (Jaffray et al., 2000). The balance l
between CPA and latexin could thus lead to either en- s
hancement or inhibition of inflammation, depending on T
other mediators present. q
One puzzling aspect is that latexin contains no signal p
speptide or predicted hydrophobic segments that couldediate secretion. In this respect, latexin could resem-
le the serpin plasminogen activator inhibitor type 2
PAI-2), which is a cytoplasmic protein located and reg-
lated quite differently from its target, plasminogen ac-
ivator (Costelloe et al., 1999). However, in mast cells,
atexin has a granular localization and associates with
subpopulation of vesicles (Uratani et al., 2000), and
e have confirmed that latexin is also expressed in a
iscrete granule population in macrophages (A. Bur-
ows, D.A.H., and S.K., unpublished data).
Latexin is thought to be a noncompetitive inhibitor of
PA (Normant et al., 1995). This mode of inhibition
akes it difficult to predict putative interaction sites,
ecause the binding site may not necessarily involve
he enzyme active site. Analysis of the latexin structure
eveals a number of features that could represent pro-
ein interaction sites, without the need to invoke con-
ormational changes. The electrostatic surface of la-
exin reveals a basic patch formed by residues from the
helices of both subdomains (Lys18 and Lys159). The
wo subdomains are arranged so that there is a cleft in
his part of the structure that could accommodate a
eptide chain. Another intriguing feature is the protrud-
ng nature of the loop incorporating a cis-peptide and
omprising residues 121–131. Clearly, it is there for a
urpose, since the cis-proline region is highly con-
erved throughout the wider latexin/TIG1 family. This
onservation is indicative of a conserved structure and
ossibly a conserved function. Conversely, there is only
ne region in the protein sequences (Figure 1) that is
ypervariable—the loop between β3 and β4. This loop
aries in length (6–14 residues) and sequence (Figure 1)
ver all eight proteins, yet it is highly conserved within
atexin or TIG1 subfamilies. The loop therefore repre-
ents a point of unusual variability in a seemingly well-
onserved protein scaffold and will be of considerable
nterest should TIG1 proteins subsequently be shown
ot to have CPI activity.
The disparate sizes and sequences of latexin and the
lant/parasite CPIs indicated a piori that they would
ncode very different protein folds, and this is borne
ut by the structural comparison (Figure 4). What was
ntirely unexpected was the striking similarity between
he subdomains of latexin and proteins of the cystatin/
onellin superfamily (Figure 4). This similarity suggests
he possiblity that latexin may have cysteine protease
nhibitor activity. However, the residues in cystatins that
re involved in binding are conserved within the cys-
atin family, but are not present in latexin. Indeed, the
equence similarity between latexin and the cystatins
s very low.
The sequence similarity between latexin and TIG1
uggests that the latter may have protease inhibitor ac-
ivity, though this is not yet tested to our knowledge.
imilarly, there is no evidence that latexin plays a tumor
uppressor role, though its partner protein CPA3 has
een shown to be induced in prostate cancer cells (Hu-
ng et al., 1999). However, if sequence identity between
atexin and the C-terminal domain of TIG1 translates to
tructural and functional similarity, it is possible that
IG1 tumor suppressor function could be a conse-
uence of extracellular proteolysis inhibition. This has
arallels elsewhere in tumor biology; for example, the
erine protease inhibitor maspin is a tumor suppressor
Cellular and Structural Studies on Latexin
315because it inhibits cell motility, invasion, and angiogen-
esis (Sager et al., 1997).
In summary, we have shown that proteolysis in gene-
ral, and latexin in particular, play a role in the immune
response, since the latexin gene is highly expressed in
macrophages and its expression is further regulated by
several proinflammatory stimuli. We solved the crystal
structure of latexin, and this unexpectedly revealed a
relationship between the carboxypeptidase inhibitor la-
texin and the cysteine protease inhibitors, cystatins.
We identified a cis-proline loop in latexin that is likely
to be important for function and that is conserved in
the tumor suppressor protein TIG1.
Experimental Procedures
Differentiation of Bone Marrow-Derived Macrophages
Bone marrow-derived macrophages were obtained from femurs of
a pool of 6- to 8-week-old male mice. Macrophages were differenti-
ated from bone marrow progenitors in RPMI1640 (BRL), 10% fetal
calf serum, and 104 U/ml (100 ng/ml) recombinant CSF-1 (a gift
from Chiron, Emeryville, CA) for 6 days. Macrophages were seeded
at 1 × 107 cells/ml and incubated with 10 ng/ml LPS from Salmo-
nella minnesota (Sigma-Aldrich, St. Louis, MO). 3 × 10 cm dishes
were harvested at each time point—unstimulated (time 0), 30 min,
2 hr, 7 hr, and 21 hr. RNA was extracted by using the RNeasy midi
kit (Qiagen) according to manufacturer’s instructions. Replica data
were derived from independent RNA extractions of a different pool
of 6- to 8-week-old mouse femurs.
Quantitative Real-Time PCR
Total RNA (2.5 g) of each sample was treated with DNase 1 (Am-
bion, Austin, TX) and reverse-transcribed by using 17mer oligo-dT
and the Superscript III RnaseH− reverse transcriptase kit, or the
Superscript III First-Strand Synthesis system for RT-PCR (Invitro-
gen). Negative control samples (no first strand synthesis) were pre-
pared by performing reactions in the absence of reverse tran-
scriptase. The reaction after reverse transcription (20 l) was
diluted to 100 l with water. Five l diluted cDNA was used for
quantitative real-time PCR performed by using the LightCycler-
DNA Master SYBR Green I kit (Roche). The PCR was performed by
using an ABI Prism machine (Applied Biosystems): 1 min hot start
at 94°C, followed by 45 cycles of 1 s at 94°C, 10 s at 60°C, and 15
s at 72°C. cDNA levels during the linear phase of amplification were
normalized against hypoxanthine phosphoribosyltransferase con-
trols. Assays were done in triplicate, and mean ± SD was deter-
mined. Primers used for the amplification of murine latexin: forward
5#-TTCGAAGGAGAAATCGGCAA-3# and reverse 5#-GGGATGTCC
TGTGCTTCCAG-3#.
Expression and Purification
A pool of cDNA species generated by using mRNA extracted from
murine bone marrow-derived macrophages treated with LPS over
a time course of up to 24 hr (Wells et al., 2003a) was used as the
template for PCR amplification. Mouse latexin cDNA (669 nucleo-
tides) was amplified by using the forward primer 5#-CACCATG
GAAATCCCACCCACCCAC-3# and reverse primer 5#-TCACTCCG
CCTGCCCTTCC-3# (start codon for translation is shown in bold) by
using Eppendorf Triple Master blunt-ended proof-reading polymer-
ase. The 50 l PCR reaction contained 10 l enzyme buffer, 100 ng
of each primer, 1 l 20 mM dNTPs, 0.5 l cDNA, and 0.3 l enzyme.
The cycling conditions included initial denaturation for 2 min at
95°C, followed by 30 cycles of denaturation at 95°C for
30 s, annealing at 55°C for 45 s, and elongation at 68°C for 1 min.
The PCR product was cloned into pENTR/D-TOPO vector with
GATEWAY (Invitrogen). The latexin gene was transferred into
pDEST-17 expression vector and expressed in E. coli as an N-ter-
minal His-tag fusion protein.
The protein was expressed in E. coli by autoinduction (W. Studier,
personal communication). A colony from an LB-Amp plate was in-
oculated into 1–2 ml defined minimal medium containing glucoseas an energy source, thereby preventing expression of genes con-
trolled by the lac-operon. After incubation at 37°C for a day, the
culture was inoculated (1/100) into a rich medium containing glu-
cose and lactose and then incubated overnight at 37°C. Typically,
OD600 was 5–6 at harvest, and the yield of latexin was 100 mg/l
culture. The His-tagged protein was purified by metal affinity chro-
matography (Talon, Clontech). After elution, the buffer was ex-
changed with 10 mM Hepes (pH 7.5), 150 mM NaCl, 10% glycerol,
1 mM DTT, and the protein was concentrated to w50 mg/ml.
Selenomethionine (SeMet)-labeled latexin was produced as de-
scribed previously for other proteins (Edeling et al., 2002) and puri-
fied in the same way as native protein. Incorporation of SeMet was
verified by mass spectrometry by using a PE SCIEX API III triple-
quadrupole mass spectrometer.
Crystal Structure
Crystals were obtained by hanging-drop vapor diffusion after 5–7
days by mixing 1 l protein solution with 1 l reservoir containing
1.8 M ammonium sulfate, 0.1 M cacodylate (pH 6.5) (space group
P43212 and unit cell dimensions a = b = 104.14 Å, c = 60.04 Å).
Crystals of SeMet latexin were grown in the same way and ap-
peared after 3–4 days. Crystals were flash-cooled after soaking for
10 s in a cryoprotectant containing 25% glycerol, 2.0 M ammonium
sulfate, and 0.1 M cacodylate (pH 6.5). X-ray diffraction data (MAD
and native) were measured at beamline 8.2.2 of the Advanced Light
Source (ALS) at Lawrence Berkeley National Laboratory (LBNL,
Berkeley, CA) and were processed and scaled by using HKL2000
(Otwinowski and Minor, 1997).
SOLVE (Terwilliger, 2003) was used to locate six seleniums and
to provide initial phases for refinement (mean figure of merit = 0.7).
Automatic model building was performed with ARP/WARP (Morris
et al., 2003) within the CCP4 package (CCP4, 1994). The resulting
model consisting of 179 amino acids was used as a starting point
for model building in O (Jones et al., 1991) and refinement by maxi-
mum likelihood and individual B factor refinement against native
data at 1.83 Å resolution with CNS (Brunger et al., 1998).
The final model includes residues 1–217 of latexin and 3 residues
from the 28-residue tag (denoted −2, −1, and 0). The five C-terminal
residues (218–222) were not included due to poor electron density.
Modeling and Analysis
Alignments between the proteins were generated by CLUSTALX
(Jeanmougin et al., 1998) with default parameters. Models for the
C-terminal region of rat, mouse, and human TIG1 corresponding to
the latexin sequence were constructed by using MODELLER (Sali
and Blundell, 1993) with mouse latexin structure as the template.
The highest refinement level in HOMOLOGY (INSIGHTII, Accelrys)
was used. The modeling procedure was iterative; in each iteration,
10 models were constructed and compared. The lowest energy
structure was used for further refinement. The stereochemical qual-
ity of models was checked by using PROCHECK (Laskowski et al.,
1993), as implemented in the Biotech validation suite at 1.9 Å reso-
lution.
Sulfate binding pockets were identified by using GRID (Good-
ford, 1985) with a charged oxygen of a sulfate or phosphate used
as a probe with grid spacing of 0.5 Å. Docking calculations were
performed by using GOLD (v2.0) (Verdonk et al., 2003) for the bind-
ing of a pentasaccharide (1AZX [Jin et al., 1997]; energy minimized
in BUILDER [INSIGHTII] by using the esff force-field) representing
mast cell granule heparin. Fifty dockings were performed in the
binding site defined as a 20 Å sphere centered on Arg171, and
these were ranked according to the GoldScore fitness function
(Verdonk et al., 2003). Cavity detection was not used; other param-
eters were set to defaults.
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